KR20210057782A - 항종양 아레나바이러스 및 아레나바이러스 돌연변이체의 제조 방법 - Google Patents

항종양 아레나바이러스 및 아레나바이러스 돌연변이체의 제조 방법 Download PDF

Info

Publication number
KR20210057782A
KR20210057782A KR1020217010631A KR20217010631A KR20210057782A KR 20210057782 A KR20210057782 A KR 20210057782A KR 1020217010631 A KR1020217010631 A KR 1020217010631A KR 20217010631 A KR20217010631 A KR 20217010631A KR 20210057782 A KR20210057782 A KR 20210057782A
Authority
KR
South Korea
Prior art keywords
leu
ser
seq
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217010631A
Other languages
English (en)
Korean (ko)
Inventor
카를 랑
코넬리아 하르트
미카엘 베르거하우젠
힐랄 바트
Original Assignee
아발로스 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아발로스 테라퓨틱스 게엠베하 filed Critical 아발로스 테라퓨틱스 게엠베하
Publication of KR20210057782A publication Critical patent/KR20210057782A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217010631A 2018-09-12 2019-09-12 항종양 아레나바이러스 및 아레나바이러스 돌연변이체의 제조 방법 Pending KR20210057782A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102018215551.8 2018-09-12
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
PCT/EP2019/074307 WO2020053324A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Publications (1)

Publication Number Publication Date
KR20210057782A true KR20210057782A (ko) 2021-05-21

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010631A Pending KR20210057782A (ko) 2018-09-12 2019-09-12 항종양 아레나바이러스 및 아레나바이러스 돌연변이체의 제조 방법

Country Status (18)

Country Link
US (2) US12129281B2 (enExample)
EP (2) EP4019533A1 (enExample)
JP (1) JP7583448B2 (enExample)
KR (1) KR20210057782A (enExample)
CN (2) CN120158432A (enExample)
AU (1) AU2019340845B2 (enExample)
BR (1) BR112021004451A2 (enExample)
CA (1) CA3111305A1 (enExample)
CL (1) CL2021000592A1 (enExample)
DE (1) DE102018215551A1 (enExample)
DK (1) DK3694868T3 (enExample)
ES (1) ES2908854T3 (enExample)
IL (1) IL281299B2 (enExample)
MX (1) MX2021002937A (enExample)
PH (1) PH12021550424A1 (enExample)
SG (1) SG11202101970UA (enExample)
WO (1) WO2020053324A1 (enExample)
ZA (1) ZA202101833B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508823A (ja) * 2021-02-26 2024-02-28 アバロス セラピューティクス ゲーエムベーハー 治療目的のための新規のウイルス粒子
WO2025046106A1 (en) * 2023-08-31 2025-03-06 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells
CN117867030A (zh) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用
CN121022940B (zh) * 2025-10-30 2026-04-07 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
KR20110074563A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
RU2585216C2 (ru) 2009-03-23 2016-05-27 Институт Пастор Мутантные полипептиды суаа и производные полипептидов, подходящие для доставки иммуногенных молекул в клетку
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
US20150307559A1 (en) 2012-12-12 2015-10-29 Children's Hospital Of Eastern Ontario Research Intitute Inc. Compositions and methods for the treatment of brain cancers
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
EP3173092B1 (en) 2015-04-22 2019-06-26 CureVac AG Rna containing composition for treatment of tumor diseases
WO2018083220A2 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Also Published As

Publication number Publication date
CN120158432A (zh) 2025-06-17
US12129281B2 (en) 2024-10-29
IL281299A (en) 2021-04-29
ZA202101833B (en) 2022-10-26
IL281299B2 (en) 2025-07-01
CN112996802B (zh) 2025-03-11
BR112021004451A2 (pt) 2021-06-01
US20250122244A1 (en) 2025-04-17
ES2908854T3 (es) 2022-05-04
AU2019340845B2 (en) 2026-01-29
CL2021000592A1 (es) 2021-09-10
MX2021002937A (es) 2021-07-16
EP3694868A1 (en) 2020-08-19
NZ774584A (en) 2024-09-27
CN112996802A (zh) 2021-06-18
SG11202101970UA (en) 2021-03-30
DK3694868T3 (da) 2022-02-07
US20220033445A1 (en) 2022-02-03
CA3111305A1 (en) 2020-03-19
EP3694868B1 (en) 2021-11-03
AU2019340845A1 (en) 2021-05-06
IL281299B1 (en) 2025-03-01
WO2020053324A1 (en) 2020-03-19
EP4019533A1 (en) 2022-06-29
DE102018215551A1 (de) 2020-03-12
JP2022500054A (ja) 2022-01-04
JP7583448B2 (ja) 2024-11-14
PH12021550424A1 (en) 2021-09-20

Similar Documents

Publication Publication Date Title
US20250122244A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
JP7273102B2 (ja) 腫瘍の治療および／または阻止において使用するためのアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）、および、（改善された）腫瘍退縮特性（ｔｕｍｏｒ－ｒｅｇｒｅｓｓｉｏｎ ｐｒｏｐｅｒｔｉｅｓ）を有するアレナウイルス（ａｒｅｎａｖｉｒｕｓｅｓ）を産生するための方法
EP3562946B1 (en) Oncolytic viruses and therapeutic molecules
WO2019184459A1 (zh) 溶瘤病毒疫苗和过继性免疫细胞联合疗法
EP3402802B1 (en) Compositions and methods for generating an immune response to a tumor associated antigen
JP2018519262A (ja) 樹状細胞免疫療法
TWI894357B (zh) 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤
JP2025503188A (ja) 腫瘍溶解性ウイルス及びその用途
CN111166867B (zh) Pd-1泛素化激动剂的功能与用途
JP2004515461A (ja) 癌治療における変異ヘルペスウイルスおよび抗癌剤の使用
RU2812046C2 (ru) Способ продуцирования аренавируса, а также мутантов аренавируса с противоопухолевыми свойствами
HK40054624A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
CN113583977B (zh) 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
HK40122461A (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
HK40054624B (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
Sinkovics Adult human sarcomas. II. Medical oncology
CN121130086A (zh) Hs2st1抑制剂在制备治疗egfr-tki耐药肿瘤的药物中的应用
CN118256561A (zh) 靶向双激酶aurka/cdk7的疫苗在治疗实体瘤中的应用
HK40012869A (en) Oncolytic viruses and therapeutic molecules

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000